Total prostatic specific antigen levels among subjects exposed and not exposed to arsenic in drinking water;Niveles séricos del antígeno prostático específico en varones expuestos y no expuestos al arsénico en el agua de bebida en Tucumán, Argentina.

Revista Medica de Chile

Volumn 139, Issue 12, 2011, Pages 1581-1587

  de González, Analía Soria ^a   Tefaha, Liliana ^a   Guber, Rosa ^a   Arias, Nilda ^a   Romero, Claudio ^a   Martínez, Mateo ^a   Valdivia, Marta ^a   Sandoval, Noemi ^a   Toledo, Roxana ^a   Czejack, María ^a  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Antigens; Arsenic; Neoplasm; Prostatic neoplasms

Indexed keywords

DRINKING WATER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARGENTINA; ARSENIC POISONING; ARTICLE; BLOOD; CHEMISTRY; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; RURAL POPULATION; STATISTICS;

ARGENTINA; ARSENIC POISONING; DRINKING WATER; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RURAL POPULATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84858143206     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872011001200007     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Schmid HP, Engeler DS, Pummer K, Schmitz-Dräger BJ. Prevention of prostate cancer: more questions than data. Recent Results Cancer Res 2007; 174: 101-7.
3. Makinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, et al. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen. Clin Cancer Res 2003; 9: 2435-9.
4. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78.
5. Nadler RB, Collins MM, Propert KJ, Mikolajczyk SD, Knauss JS, Landis JR, et al. Chronic Prostatitis Collaborative Research Network Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology 2006; 67: 337-42.
6. Wolf A, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer. Update 2010. CA Cancer J Clin 2010; 60: 70-98.
7. Crawford ED, Leewansangtong S, Goktas S, Holthaus K, Baier M. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate 1999; 38: 296-302.
8. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and metaanalysis. Eur Urol 2005; 48: 386-98; discussion 398-9.
9. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some drinking-water disinfectants and contaminants, including arsenic. IARC Monogr Eval Carcinog Risks Hum 2004; 84: 269-477.
11. Benbrahim-Tallaa L, Waalkes MP. Inorganic arsenic and human prostate cancer. Environ. Health Perspect 2008; 116: 158-64.
12. Guber RS, Tefaha L, Arias NN, Sandoval NG, Toledo R, Fernandez M, et al. Contenido de arsénico en el agua de consumo en Leales y Graneros (Provincia de Tucumán-Argentina). Acta Bioquím Clín Latinoam 2009; 43: 201-7.
13. U.S. EPA. Arsenic, Inorganic (CASRN 7440-38-2), Integrated Risk Information System. Washington, DC: U.S. Environmental Protection Agency 1993. Available: http://www.epa.gov/iris/subst/0278.htm [31 March 2005].
14. International Agency for Research on Cancer. Arsenic and arsenic compounds. IARC Monogr Eval Carcinog Risks Hum 1987; 23: 100-3.
15. Tokar EJ, Qu W, Liu J, Liu W, Webber MM, Phang JM, Waalkes MP. Arsenic-specific stem cell selection during malignant transformation. J Natl Cancer Inst 2010; 102: 638-49.
16. Rivara MI, Corey G. Tendency to die of cancers associated to chronic exposure to arsenic, II Region of Antofagasta, 1950-1993. Cuad Méd Soc (Chile) 1995; 36: 39-51.
17. Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, von Ehrenstein O, et al. Increased Mortality from Lung Cancer and Bronchiectasis in Young Adults Following Exposure to Arsenic In Utero and Early Childhood. Environ Health Perspect 2006; 114: 1293-6.
18. Ministerio de Salud de la Nación. Secretaría de Políticas, Regulación e Institutos. Dirección de Estadísticas e Información de salud. Estadísticas vitales. Información básica-2008. Serie 5, Número 52, 2009. Disponible en http://www.deis.gov.ar/Publicaciones/Archivos/Serie5Nro52. pdf. [Consultado el 15 de octubre de 2010].
19. Huang YK, Huang YL, Hsueh YM, Yang MH, Wu MM, Chen SY, et al. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. Cancer Causes Control 2008; 19: 829-39.
20. Tseng CH. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007; 25: 1-22.
21. Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, et al. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol Appl Pharmacol 2010; 247: 138-45.
22. Hopenhayn-Rich C, Biggs Smith H. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol 1998; 27: 561-9.
23. Soria de González A, Guber R, Martínez M, Arias N, Tefaha L, Sandoval N, et al. Alteraciones bioquímicas en individuos expuestos al arsénico en el agua de bebida en Tucumán, Argentina. Acta Bioquím Clín Latinoam 2009; 43: 611-8.
24. Chen CJ, Kuo TL, Wu MM. Arsenic and cancers. Lancet 1988; 1: 414-5.
25. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect 1999; 107: 359-65.
26. Hinwood AL, Jolley DJ, Sim MR. Cancer incidence and high environmental arsenic concentrations in rural populations: results of an ecological study. Int J Environ Health R 1999; 9: 131-41.
27. Pant N, Murthy RC, Srivastava SP. Male reproductive toxicity of sodium arsenite in mice. Hum Exp Toxicol 2004; 23: 399-403.
28. Hsieh FI, Hwang TS, Hsieh YCh, Lo HCh, Su ChT, Hsu HS, et al. Risk of Erectile Dysfunction Induced by Arsenic Exposure through Well Water Consumption in Taiwan. Environ Health Perspect 2008; 116: 532-36.
29. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005; 165: 1857-61.
30. Graham J, Baker M, Macbeth F, Titshall V. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 2008; 336: 610-2.
31. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5.
32. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤ 4.0 ng per Milliliter. N Engl J Med 2004; 350: 2239-46.